115 related articles for article (PubMed ID: 10892662)
1. Ibudilast modulates platelet-endothelium interaction mainly through cyclic GMP-dependent mechanism.
Kishi Y; Ohta S; Kasuya N; Tatsumi M; Sawada M; Sakita S; Ashikaga T; Numano F
J Cardiovasc Pharmacol; 2000 Jul; 36(1):65-70. PubMed ID: 10892662
[TBL] [Abstract][Full Text] [Related]
2. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells.
Rile G; Yatomi Y; Qi R; Satoh K; Ozaki Y
Thromb Res; 2001 May; 102(3):239-46. PubMed ID: 11369417
[TBL] [Abstract][Full Text] [Related]
5. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors.
Salvemini D; Radziszewski W; Korbut R; Vane J
Br J Pharmacol; 1990 Dec; 101(4):991-5. PubMed ID: 1707709
[TBL] [Abstract][Full Text] [Related]
6. Atrial natriuretic peptide reduces cyclic AMP by activating cyclic GMP-stimulated phosphodiesterase in vascular endothelial cells.
Kishi Y; Ashikaga T; Watanabe R; Numano F
J Cardiovasc Pharmacol; 1994 Sep; 24(3):351-7. PubMed ID: 7528289
[TBL] [Abstract][Full Text] [Related]
7. Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model.
Takuma K; Lee E; Enomoto R; Mori K; Baba A; Matsuda T
Br J Pharmacol; 2001 Jul; 133(6):841-8. PubMed ID: 11454657
[TBL] [Abstract][Full Text] [Related]
8. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.
Souness JE; Villamil ME; Scott LC; Tomkinson A; Giembycz MA; Raeburn D
Br J Pharmacol; 1994 Apr; 111(4):1081-8. PubMed ID: 8032594
[TBL] [Abstract][Full Text] [Related]
9. Exogenous GTP increases cyclic GMP and inhibits thrombin-induced aggregation of washed human platelets: comparison with ATP, adenosine and guanosine.
Vuorinen P; Laustiola KE
Pharmacol Toxicol; 1992 Oct; 71(4):289-93. PubMed ID: 1333596
[TBL] [Abstract][Full Text] [Related]
10. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
11. Relaxation and potentiation of cGMP-mediated response by ibudilast in bovine tracheal smooth muscle.
Nakahara T; Yunoki M; Moriuchi H; Mitani A; Sakamoto K; Ishii K
Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):262-9. PubMed ID: 12172709
[TBL] [Abstract][Full Text] [Related]
12. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.
Delpy E; Coste H; Gouville AC
Br J Pharmacol; 1996 Oct; 119(3):471-8. PubMed ID: 8894166
[TBL] [Abstract][Full Text] [Related]
13. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
14. Effect of trilinolein on cyclic nucleotide formation in human platelets: relationship with its antiplatelet effect and nitric oxide synthesis.
Shen YC; Hong CY
Br J Pharmacol; 1995 Sep; 116(1):1644-8. PubMed ID: 8564231
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process.
Chou TC; Li CY; Yen MH; Ding YA
Biochem Pharmacol; 1999 Nov; 58(10):1657-63. PubMed ID: 10535758
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet activity of caffeic acid phenethyl ester is mediated through a cyclic GMP-dependent pathway in human platelets.
Chen TG; Lee JJ; Lin KH; Shen CH; Chou DS; Sheu JR
Chin J Physiol; 2007 Jun; 50(3):121-6. PubMed ID: 17867432
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
18. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.
Yu SM; Kuo SC
Br J Pharmacol; 1995 Apr; 114(8):1587-94. PubMed ID: 7599926
[TBL] [Abstract][Full Text] [Related]
19. Conversion of glyceryl trinitrate to nitric oxide in tolerant and non-tolerant smooth muscle and endothelial cells.
Salvemini D; Pistelli A; Vane J
Br J Pharmacol; 1993 Jan; 108(1):162-9. PubMed ID: 8381319
[TBL] [Abstract][Full Text] [Related]
20. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
Hirose R; Okumura H; Yoshimatsu A; Irie J; Onoda Y; Nomoto Y; Takai H; Ohno T; Ichimura M
Eur J Pharmacol; 2001 Nov; 431(1):17-24. PubMed ID: 11716838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
